Daskal Ilan's most recent trade in Viavi Solutions Inc was a trade of 82,095 Common Stock done at an average price of $9.3 . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Sale of securities on an exchange or to another person at price $ 9.28 per share. | 04 Jun 2025 | 82,095 | 0 (0%) | 0% | 9.3 | 761,842 | Common Stock |
| Viavi Solutions Inc | Daskal Ilan | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 65,944 | 197,830 | - | - | Restricted Stock Unit | |
| Viavi Solutions Inc | Daskal Ilan | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 65,944 | 96,835 (0%) | 0% | 0 | Common Stock | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 39,783 | 39,783 (0%) | 0% | 0 | Common Stock | |
| Viavi Solutions Inc | Daskal Ilan | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 39,783 | 197,831 | - | - | Market Stock Units | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 37,879 | 75,757 | - | - | Restricted Stock Unit | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 37,879 | 101,293 (0%) | 0% | 0 | Common Stock | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 28 Nov 2024 | 33,421 | 63,414 (0%) | 0% | 9.9 | 330,199 | Common Stock |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 22,851 | 42,472 (0%) | 0% | 0 | Common Stock | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2024 | 22,851 | 75,758 | - | - | Market Stock Units | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 28 Nov 2024 | 20,162 | 19,621 (0%) | 0% | 9.9 | 199,201 | Common Stock |
| Viavi Solutions Inc | Daskal Ilan | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 28 Nov 2024 | 19,198 | 82,095 (0%) | 0% | 9.9 | 189,676 | Common Stock |
| Viavi Solutions Inc | Daskal Ilan | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 28 Nov 2024 | 11,581 | 30,891 (0%) | 0% | 9.9 | 114,420 | Common Stock |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2024 | 39,783 | 39,783 | - | - | Market Stock Units | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2024 | 22,851 | 22,851 | - | - | Market Stock Units | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 165,343 | 165,343 | - | - | Restricted Stock Unit | |
| Viavi Solutions Inc | Ilan Daskal | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 165,343 | 165,343 | - | - | Market Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2023 | 4,007 | 4,007 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 694 | 2,082 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 694 | 2,206 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 542 | 542 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 542 | 2,755 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 456 | 912 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 456 | 2,422 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 269 | 2,486 (0%) | 0% | 394.6 | 106,147 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 240 | 1,966 (0%) | 0% | 394.6 | 94,704 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 394.60 per share. | 01 Sep 2023 | 209 | 2,213 (0%) | 0% | 394.6 | 82,471 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 700 | 700 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 700 | 1,736 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 466.24 per share. | 08 Apr 2023 | 243 | 1,493 (0%) | 0% | 466.2 | 113,296 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 541 | 1,084 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2022 | 541 | 1,222 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 478.32 per share. | 02 Sep 2022 | 269 | 953 (0%) | 0% | 478.3 | 128,668 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 2,776 | 2,776 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 455 | 1,368 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 455 | 907 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 486.25 per share. | 01 Sep 2022 | 226 | 681 (0%) | 0% | 486.3 | 109,893 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 700 | 709 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 700 | 1,400 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 597.16 per share. | 08 Apr 2022 | 257 | 452 (0%) | 0% | 597.2 | 153,470 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 820.06 per share. | 03 Sep 2021 | 270 | 9 (0%) | 0% | 820.1 | 221,416 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 1,823 | 1,823 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 1,823 | 1,823 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 541 | 548 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 541 | 1,625 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 524.30 per share. | 01 Sep 2021 | 540 | 547 (0%) | 0% | 524.3 | 283,122 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 540 | 1,626 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 828.00 per share. | 01 Sep 2021 | 440 | 107 (0%) | 0% | 828 | 364,320 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 825.77 per share. | 01 Sep 2021 | 269 | 279 (0%) | 0% | 825.8 | 222,132 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 828.01 per share. | 01 Sep 2021 | 100 | 7 (0%) | 0% | 828.0 | 82,801 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 309.84 per share. | 04 Aug 2021 | 1,400 | 2,307 (0%) | 0% | 309.8 | 433,776 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 1,400 | 2,100 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 751.98 per share. | 04 Aug 2021 | 954 | 496 (0%) | 0% | 752.0 | 717,389 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 750.85 per share. | 04 Aug 2021 | 857 | 1,450 (0%) | 0% | 750.8 | 643,478 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 753.32 per share. | 04 Aug 2021 | 489 | 7 (0%) | 0% | 753.3 | 368,373 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 700 | 1,157 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 700 | 2,100 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 592.23 per share. | 08 Apr 2021 | 250 | 907 (0%) | 0% | 592.2 | 148,058 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 2,166 | 2,166 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc. ... | Ilan Daskal | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 2,166 | 2,166 | - | - | Non-Qualified Stock Option (right to buy) |